Insider Purchases: Inside the Buy
Tag: ShortSqueeze
🧥 G-III Apparel (GIII): CEO Buys $1.12M at $27.94 as Marc Jacobs Becomes the $1B Bet 👗👜
G-III CEO Morris Goldfarb just invested $1.12 million in GIII at $27.94 as the apparel group trades below book value and transforms its brand portfolio around owned labels and Marc Jacobs. With expanding Q2 margins, roughly 21% short float and major execution risks, is Wall Street putting this fashion turnaround on the clearance rack too soon?
🚀 Karman Space & Defense (KRMN): $1.03M Insider Buying, $1.3B Backlog & 58% Revenue Growth
Three Karman Space & Defense directors just bought roughly $1.03 million of KRMN near $37 after a brutal 70% drawdown. Meanwhile, Q2 revenue surged 58%, backlog hit $1.3 billion and guidance rose. The business is firing—but at roughly 44x forward earnings, is the stock finally cheap enough?
🤖 Upstart (UPST): $7.65M Founder Buying Meets a 30.6% Short-Squeeze Fuse 💳⚡
Upstart CEO Paul Gu and Executive Chairman Dave Girouard have bought roughly $7.65 million of UPST stock. Now revenue is growing 42%, GAAP profitability has returned—and 30.6% of the float is short. We dissect one of fintech’s most fascinating battleground stocks.
🩺 Alphatec (ATEC): CEO’s $1M Buy, Positive Free Cash Flow & an 11% Short-Squeeze Fuse 🦾🦴
Alphatec CEO Pat Miles just put $1.01 million of his own money into ATEC at $8.81. With positive free cash flow, improving EBITDA, Valence robotics and 11% short interest, is this battered spine-medtech stock finally reaching its turnaround moment?
🎮 GameStop (GME): Insider Stacking, $5.4B Cash Pile, $4.9B eBay Stake & the Collectibles Pivot 📦🕹️
GameStop isn't merely the meme stock it used to be. With Ryan Cohen and Lawrence Cheng buying shares, record Q2 operating income, collectibles sales up 57%, $5.4 billion in financial assets and a $4.9 billion eBay stake, GME is evolving into a fascinating—and extremely volatile—special situation.
🦴 Enovis (ENOV): CEO Buys the $19 Crash—Is This Falling Knife Finally a Buy? 🤖
Enovis CEO Damien McDonald bought ENOV again after shares collapsed toward $19. Insiders are accumulating, institutions remain heavily invested, analysts see substantial upside and adjusted valuation has fallen below 5x forward earnings. But short interest is high, leverage and integration risks remain—and momentum is dreadful. ENOV may be the ultimate FunStock signal collision.
🧬 Kura Oncology (KURA) Stock Analysis: From Clinical Promise to Commercial Reality
Kura Oncology is evolving from a clinical-stage biotech into a commercial oncology company. With KOMZIFTI gaining traction, over $500 million in cash, strong institutional ownership and multiple Phase 3 catalysts ahead, is KURA becoming one of biotech's most compelling long-term opportunities?
⚡ Ameresco (AMRC): The AI Power Boom, a $1.17M Insider Buy, and a $6.73B Backlog
Artificial intelligence doesn't just require better chips—it requires vastly more electricity. Ameresco sits at the intersection of AI infrastructure, energy modernization, and microgrids, backed by a record $6.73 billion backlog, significant insider buying, and improving operational momentum. The opportunity is compelling, but so are the risks.
🧬 Ionis Pharmaceuticals (IONS): The RNA Arbitrage — $2.1B Cash, $1M Insider Buy, and the Post-Trial Collapse
Ionis Pharmaceuticals (NASDAQ: IONS) lost billions in market value after a disappointing clinical trial—but one director immediately bought more than $1 million worth of shares. Is Wall Street missing the bigger RNA platform story? Here's the full analysis.
🛒 Albertsons (ACI): Wall Street Gave Up. One Executive Just Invested $1.96 Million.
Albertsons has disappointed Wall Street—but one executive just invested nearly $2 million of his own money. We examine the insider buy, valuation, operating cash flow, ACI Edge restructuring, dividend sustainability and whether ACI could become one of the market's more interesting turnaround stories.